---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-25-002271"
form_type: "8-K"
ticker: "HOTH"
cik: "0001711786"
company_name: "Hoth Therapeutics, Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:51:24.811618+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Hoth restates 2023, 2024 financials for prepaid R&D errors; initiates HT-KIT toxicity study

## Summary
- Restatement: prepaid expenses understated by $722,765 at Dec 31, 2023; R&D expenses understated by $260,732 for FY2023.
- Quarterly restatements for 2023-2024: prepaid assets understated by $442k-$983k; R&D expenses understated by $52k-$280k.
- Enters Project Order with OnTargetx for 4-week IV toxicity study of HT-KIT (mast cell cancer) at cost of $354,219.
- Restatement impacts operating cash flows but total cash unchanged; 2024 10-K to include restated periods.

## SEC filing metadata
- accession: 0001013762-25-002271
- form_type: 8-K
- ticker: HOTH
- cik: 0001711786
- company_name: Hoth Therapeutics, Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000101376225002271/0001013762-25-002271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000101376225002271/ea0235633-8k_hoth.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-25-002271
- JSON: https://secwatch.observer/filing/0001013762-25-002271.json
- Plain text: https://secwatch.observer/filing/0001013762-25-002271.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.